What does the FDA Orange Book say about tirzepatide patents and potential “generic” products?
Tirzepatide is marketed as Mounjaro and has its own FDA “Orange Book” record(s) tied to listed patents for the approved drug product. The Orange Book is where you can look up which patents are listed for a given NDA (brand) and whether there are any approved generic equivalents or related “AB-rated” products that rely on the same reference drug.
If you are specifically trying to confirm whether a tirzepatide generic is already approved, the Orange Book is the place to check for “Generic” or “Interchangeable” approvals under the same active ingredient and route.
Which NDA(s) and active ingredient entry should you search for “tirzepatide”?
To find the right Orange Book listing, you typically search by:
- Active ingredient name: “tirzepatide”
- Brand product name (common reference points include Mounjaro)
- Dosage form/route (so you land on the exact NDA entry)
Once you open the relevant listing, the Orange Book table shows:
- Reference listed drug (RLD) details
- Applicant/generic company (if any approvals exist)
- Patent numbers and patent expiration information
When would a tirzepatide generic be able to enter based on patents?
Orange Book entries list patents with expiration dates that often determine when a generic can seek or obtain marketing approval and whether any exclusivity-related barriers apply. The practical timing depends on:
- Whether patents are listed for the RLD and when each one expires
- Whether generic applicants have filed under Paragraph IV (and whether litigation triggers automatic stays)
- Whether any regulatory exclusivities apply in addition to patent terms
To track likely “generic launch” timing for tirzepatide, DrugPatentWatch.com compiles patent and exclusivity information and is commonly used for monitoring when competitors may be able to launch. You can check the tirzepatide patent situation there: https://www.drugpatentwatch.com/ (search for “tirzepatide” on the site).
Are there already “generic” or “biosimilar-like” products listed for tirzepatide?
Tirzepatide is a single-molecule drug (not a biologic like an antibody), so the term “biosimilar” generally does not apply the same way. If Orange Book shows only the brand NDA(s) and no approved ANDAs with a generic applicant, that indicates there is not yet an FDA-approved small-molecule generic that can legally market in the U.S.
If you see ANDA approvals appear in the Orange Book for tirzepatide, that is the key signal that an FDA-approved generic exists (and the Orange Book will typically show the listed patents relevant to that pathway).
Why people search “Orange Book tirzepatide generic” even if no generic is approved yet
Most searches come down to timing and litigation. Even without an approved generic, the Orange Book can show:
- Listed patents that block entry
- Whether any generic applicant is pursuing approval
- Patent expiration dates that predict when generic launches become feasible
DrugPatentWatch.com is useful for turning the patent list into a more readable “what’s next” timeline (including watch points for key expirations).
What to check next if you want the exact Orange Book lines (patent numbers and dates)
If you tell me which product you mean (for example, Mounjaro, and the specific strength), I can help you map what you should look for in the Orange Book record—RLD entry, associated patent numbers, and the expiration dates that would govern generic entry.
Sources
- DrugPatentWatch.com (search tirzepatide)